Thousand Oaks-based biotech giant Amgen's revenues rose 11 percent in the first quarter to $6.2 billion but earnings per share dipped 3 percent to $3.07 apiece. Sales volumes increased, offset by lower overall prices, Amgen said in filings with regulators April 30. Net income fell 8 percent compared to the previous first quarter to $1.83…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
